Detailed Narrative
Strong Q1 FY26 Performance and Margin Expansion
Lupin commenced FY26 with robust financial results, achieving double-digit growth in both revenues and profitability. The company reported sales of INR 6,164 crores, an 11.8% increase year-over-year from INR 5,514 crores in Q1 FY25. EBITDA (excluding Forex and other income) rose by 27.6% YoY to INR 1,641 crores, leading to a significant EBITDA margin expansion of 330 basis points YoY, reaching 26.6% for the quarter. Gross margins also improved by 290 basis points YoY to 71.3%, driven by a better product mix and cost efficiencies.
US Business Milestones and Strategic Launches
The US business achieved its highest revenues since Q4 FY2017, recording USD 282 million, a 22.3% YoY and 12.8% QoQ growth on a constant currency basis. This was primarily driven by the successful launch of Tolvaptan with sole first-to-file exclusivity in late May, which contributed partially to the quarter's results. Management expects Tolvaptan to achieve approximately 25% market share by the end of Q2 or Q3 FY26. Additionally, Lupin secured FDA approvals for generic Victoza® and Glucagon, with Liraglutide planned for an October launch and Risperdal Consta® expected to be approved in September.
India and Other Developed Markets Show Solid Growth
The India region demonstrated a 7.8% YoY growth, with the India Formulations business growing 8.6%, aligning with IPM growth. The chronic share of the India business increased to 65% from 64% last year, despite a negative impact from Loss of Exclusivity (LOE) on certain in-licensed diabetes brands. Other Developed Markets grew 17% YoY to INR 775 crores, with Europe being a key driver, increasing by an impressive 28% YoY. These markets now constitute 13% of total sales, up from 11% two years ago, reflecting sustained momentum.
Intensified R&D Focus on Complex and Specialty Products
Lupin's R&D expenses stood at INR 484 crores, representing 7.9% of sales, a 151 basis point increase YoY from 6.3% in Q1 FY25. A significant portion, approximately 70%, of R&D investments are directed towards complex and specialty products, including injectables, respiratory, biosimilars, and 505(b)(2) products. The company anticipates R&D spend to be between 7.5% and 8.5% of sales for the full FY26, underscoring its commitment to building a robust differentiated pipeline.
Regulatory Compliance and Operational Efficiencies
On the compliance front, Lupin received an EIR for its Nagpur Unit-2 site during the quarter. However, observations were noted in 483s issued for Pithampur Unit-2 and Unit-3 sites, which management is confident of addressing effectively. Operational efficiencies and a favorable product mix contributed to the 290 basis points YoY improvement in gross margins. Employee benefit expenses increased by 11.5% YoY to INR 1,083 crores, while manufacturing and other expenses rose by 10.9% YoY to INR 1,772 crores.
Strategic Pipeline and Future Growth Drivers
Lupin is actively expanding its specialty business organically and inorganically, with over 80 product launches planned for India over the next five years. The company's position in Inhalation is rapidly expanding across the US, India, and Europe. Biosimilars are emerging as a significant platform, with Pegfilgrastim expected to be filed this fiscal year and Ranibizumab having a goal date in June '26. The company is also actively developing NaMuscla® for rare neurology, with a US launch anticipated in FY29, targeting a market opportunity of USD 100 million to USD 200 million.